Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • 2021 Webinar: AASLD’s Thought Leaders Series: How I Manage My Practice

    Product not yet rated Contains 1 Component(s) Recorded On: 10/20/2021

    Webinar hosted by the AASLD President on Wednesday, October 20.

    This 60-minute discussion, held Wednesday, October 20th and hosted by AASLD President, Dr. Ray Chung, FAASLD of Massachusetts General, included interviews with NAFLD/NASH experts, Dr. Mary Rinella, FAASLD of Northwestern University and Dr. Anna Mae Diehl, FAASLD of Duke University. Our experts delved into how they manage their practices in fatty liver, how their institutions and multidisciplinary teams work together, diagnostic and treatment solutions to NAFLD, and more.

    This webinar is the first of a new program, AASLD's Thought Leaders Series: How I Manage My Practice. These webinars will feature well-known leaders providing important clinical insights around specific liver conditions and a first-hand account of their experiences. 

    Anna Mae Diehl

    Anna Mae Diehl, MD, FAASLD is currently the Florence McAlister Professor of Medicine at Duke University.  She is a physician scientist and academic hepatologist.  Her lab-based research activities focus on basic mechanisms of liver repair and complement her translational/clinical research programs in alcoholic- and nonalcoholic fatty liver disease.  In the past two years, Dr. Diehl she has co-authored ten peer-reviewed manuscripts on these topics.

    Her basic research program has enjoyed uninterrupted NIH RO1 support since 1990 and she has been the Principal Investigator for the NASH CRN UO1 clinical research program at Duke since its inception over 15 years ago. Dr. Diehl’s research contributions to the fields of regenerative medicine, alcohol-related liver disease and NAFLD have been acknowledged by election for membership in the American Society for Clinical Investigation, Interurban Clinical Club, Association of Academic Professors and Johns Hopkins University Society of Scholars, as well as awards such as an NIH/NIAAA Merit Award, the NIAAA Mendelson Award, the Duke Distinguished Faculty Award, and the AASLD Distinguished Scientific Achievement Award. 

    Dr. Diehl has been an associate editor/editorial board member for major journals such as HEPATOLOGY, Gastroenterology, GUT, The American Journal of Physiology, The Journal of Clinical Investigation, Nature Reviews, and eLife.  In addition, she has served as a standing member of several NIH study sections and scientific advisory councils for NIDDK, NCI, NIAAA, the American Liver Foundation, the Alcoholic Beverage Medical Research Foundation, NIDDK Digestive Disease Centers at Baylor, USC and U Pittsburgh, and NIAAA Alcohol Research Centers at U Louisville and the Cleveland Clinic.  

    Mary E. McCarthy Rinella

    Mary E. Rinella, MD is a Professor of Medicine at Northwestern University Feinberg School of Medicine and is the Director of the Northwestern Fatty Liver Program. She received her medical degree from the University of Illinois.  She completed her residency training in Internal Medicine at the University of Chicago and her fellowship in Gatroenterology and Hepatology at Northwestern University, where she remains on faculty.  She studied basic mechanisms of steatohepatitis with the support of the American Gastroenterological Association and the National Institute of Health for 10 years.  Currently her focus is in clinical research in the area of non-alcoholic fatty liver disease/NASH both before and after liver transplantation. Her primary clinical focus within the NASH realm is on the associations between NASH and other metabolic co-morbidities, emerging NASH therapeutics and the recurrence of NASH after liver transplantation.  She established a multicenter consortium to study the risk factors for liver disease recurrence and outcomes of patients transplanted for NASH cirrhosis (NailNASH Consortium).  Dr. Rinella is actively involved in the American Association for the Study of Liver Diseases where she currently serves as Councilor-at-large on the Governing Board.  She has held several national leadership roles in the field of NAFLD including Chair of the AASLD NAFLD Special Interest Group (SIG) and most recently as Chair of the AASLD NASH Task Force.  As Chair of the NASH Task Force, she is charged with fostering research collaboration and advancing best practice through collaboration with other medical societies, federal agencies and patient advocacy organizations.

    Raymond Chung (Moderator)

    Raymond Chung, MD, FAASLD is Director of Hepatology and the Liver Center, Vice Chief of Gastroenterology and the Kevin and Polly Maroni Research Scholar atMassachusetts General Hospital. He has been an internationally recognizedresearcher in the areas of HCV virology and pathogenesis. He directs an NIHCooperative Center for Human Immunology centered on HCV, and is co-PI of theHarvard HBV Consortium of the NIH HBV Research Network. He is contact PI of hisDivisional T32 Training Grant, and holds several NIH R01 grants and an NIH K24Mentorship Award.

    He was recently Associate Editorof HEPATOLOGY and has previously served as a Councilor at Large for the AASLD.He has also served as co-Chair of the AASLD/IDSA HCV Guidance panel which ischarged with issuing treatment recommendations for hepatitis C. He has authoredmore than 300 original articles, reviews, and editorials.

  • 2021 Webinar: Microbiome in NASH and Cirrhosis

    Contains 2 Component(s) Recorded On: 10/13/2021

    Webinar hosted by the Nonalcoholic Fatty Liver Disease Special Interest Group on October 13, 2021.

    In this one-hour webinar, learn about the pathophysiology of microbiome and liver disease, microbiome in NASH and microbiome in cirrhosis and other liver conditions.

    Suzanne Devkota

    Suzanne Devkota, PhD is Director of Microbiome Research at Cedars-Sinai Medical Center in Los Angeles and Assistant Professor of Medicine at UCLA, as well as an adjunct investigator at the Joslin Diabetes Center at Harvard Medical School. She completed her doctoral and post-doctoral training at The University of Chicago and Joslin Diabetes Center/Harvard Medical School respectively and is a former Branco Weiss Fellow.

    Professor Devkota has been studying the effect of diet on the gut microbiome and inflammatory diseases for the past 12 years. Investigating the dietary drivers of gut microbiome structure and function in inflammatory bowel diseases and metabolic diseases. More recently, her lab has developed interest in studying the microbial ecology of gut bacterial translocation in the human body. Interest lies in the study of commensal microbes that take advantage of impaired host defenses to turn pathogenic.

    Rohit Loomba

    Rohit Loomba, MD is a Professor of Medicine (with tenure), Director of Hepatology and Vice Chief, Division of Gastroenterology at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) and non-invasive assessment of steatosis and fibrosis using advanced imaging modalities.

    Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points and integrated OMICs using microbiome, metabolome and lipidome.

    Jasmohan S. Bajaj

    Jasmohan S. Bajaj, MBBS, MD, MS, FACG, AGAF, FRCP, FAASLD is Professor of Medicine, Division of Gastroenterology, Hepatology, and Nutrition at Virginia Commonwealth University and Richmond, VA Medical Center in Richmond, VA. He is a Fellow of the American College of Gastroenterology, American Gastroenterological Association, American Association for the Study of Liver Diseases, was elected to the Fellowship of the Royal College of Physicians in London and to the American Society for Clinical Investigation. Dr. Bajaj earned his MBBS from Delhi University at Maulana Azad Medical College. He completed an internship in internal medicine at Delhi University at Maulana Azad Medical College and internal medicine residency at the State University of New York Health Science Center in Brooklyn. He furthered his medical training with a fellowship in gastroenterology and hepatology at the Medical College of Wisconsin Affiliated Hospitals, then went on to earn an MS in epidemiology at the Medical College of Wisconsin in Milwaukee.

    Active in research, Dr. Bajaj has served as a principal investigator or co-investigator for numerous clinical trials in areas such as hepatic encephalopathy, chronic liver disease and microbiome. Dr. Bajaj’s research has been funded through the NIH, US Veterans Affairs, AHRQ, and American College of Gastroenterology. His work has been published in Nature, New England Journal of Medicine, Gastroenterology, Journal of Hepatology, Hepatology, The American Journal of Gastroenterology, and Liver Transplantation, among others. Dr Bajaj is the upcoming Co-Editor in Chief for the American Journal of Gastroenterology and is currently an associate Editor for the Red Journal and Gut Microbes. He is on the editorial board for Journal of Hepatology, Hepatology, and Liver Transplantation. He was a member of the AASLD/EASL Hepatic Encephalopathy Guidelines Writing Committee, is the Chairperson of the Acute-on-Chronic Liver Failure ACG Clinical Guidelines and a member of the AASLD ICU and ACLF Guidance committee. He is also a member of the AASLD Clinical Research Committee. Dr Bajaj is the Chairperson for the North American Consortium for Study of End-Stage Liver Disease and was the immediate Past President of the International Society for Hepatic Encephalopathy and Nitrogen Metabolism.

    Stephen A. Harrison (Moderator)

    Stephen Harrison, MD, FACP, FAASLD earned his medical degree from the University of Mississippi School of Medicine. He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center and a 4th year advanced liver disease fellowship at Saint Louis University. He is board certified in both Internal Medicine and Gastroenterology.

    Dr. Harrison is a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford. He is internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with over 200 peer reviewed publications in these fields. Dr Harrison currently serves as the Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research in San Antonio, Texas.

  • 2021 Webinar: Promoting Equity, Diversity and Inclusion in Communication Near the End of Life

    Contains 2 Component(s) Recorded On: 09/30/2021

    Webinar hosted by the Membership and Mentorship Committee and Inclusion and Diversity Committee on Thursday, September 30.

    The purpose of this webinar is to present strategies to approach patient and family communication near the end-of-life in the setting of advanced liver disease with a focus on issues related to equity, diversity and inclusion. Patients with advanced liver disease experience high symptom burden, emotional distress, and prognostic uncertainty which makes them particularly vulnerable to suboptimal end-of-life care. In addition, prior work from other serious illnesses has highlighted the influence of cultural background including race, ethnicity, religion, sexual orientation, gender and other forms of identity on patients’ end-of-life care experiences and outcomes. In this webinar we will present a series of case scenarios that highlight the importance of approaching end-of-life communications with cultural humility and strategies to develop patient- and family-centered communication skills that acknowledge their voices, concerns, values, and lived experiences. The webinar will include a panel session, case-based presentations, and audience questions and discussion. The panel will consist of physicians with professional expertise that includes hepatology, palliative care, health services research, and health disparities research, and the intended audience is clinicians who provide care to people with liver diseases and their families and informal caregivers.

    Nneka Ufere

    Nneka N. Ufere, MD is a Transplant Hepatologist in the Division of Gastroenterology within the Department of Medicine at Massachusetts General Hospital and Harvard Medical School in Boston, MA. She attended Washington University in St. Louis School of Medicine where she completed her medical degree in 2012. She completed her residency training in internal medicine at Massachusetts General Hospital, where she also served as a Chief Medical Resident during the 2016-2017 academic year. She completed her Gastroenterology fellowship in 2020 and Transplant Hepatology fellowship in 2021 at Massachusetts General Hospital. She is currently pursuing a Master of Science in Clinical Epidemiology degree at the at the Harvard T. H. Chan School of Public Health.

    Dr. Ufere’s research interests center around palliative and supportive care and informed decision-making with the goal of developing interventions aimed at improving the quality of life and quality of care for patients with advanced liver disease and their caregivers. Her work is currently supported by a Clinical, Translational and Outcomes Research Award from the American Association for the Study of Liver Diseases and the Massachusetts General Hospital Physician Scientist Development Award. She is a past recipient of the NIH Loan Repayment Award, the American College of Gastroenterology Clinical Research Pilot Award and an Advanced/Transplant Hepatology Award from the American Association for the Study of Liver Diseases.

    Christopher Woodrell

    Christopher Woodrell, MD, MS is a health services researcher and board-certified internist and palliative care physician at the Icahn School of Medicine at Mount Sinai in New York City, where he is an appointed Assistant Professor. He is also Staff Physician within the Geriatric Research, Education and Clinical Center (GRECC) at the James J. Peters VAMC in the Bronx, NY. He received his Medical Doctorate, Internal Medicine Training, and Hospice and Palliative Medicine fellowship training at Mount Sinai.

    Dr. Woodrell's career goal is to help improve quality of life experienced by people facing advanced liver disease and liver cancer. His research focus is developing and testing early palliative care interventions for people with hepatocellular carcinoma and their family caregivers. He completed undergraduate training in biochemistry at Swarthmore College in Pennsylvania.

    Arpan A. Patel

    Aran A. Patel, MD, PhD is a transplant hepatologist and health services researcher at the David Geffen School of Medicine at UCLA. He is also a staff physician at the West Los Angeles Veterans Affairs Center and core investigator at the VA Center for the Study of Healthcare Innovation, Implementation and Policy (CSHIIP) in Los Angeles. He performed his residency in Internal Medicine at the Hospital of the University of Pennsylvania, followed by fellowship in gastroenterology at UCLA and fellowship in Transplant Hepatology at Mount Sinai. He completed a PhD in Health Policy and Management at the Fielding School of Public Health at UCLA in 2020. 

    Dr. Patel’s career goal is to ensure that patients with advanced liver disease receive high-value care that optimizes their quality of life. His research goal is to understand ways that principles of palliative care can be integrated in management of these patients and their caregivers.

    Julius Wilder

    Julius Wilder, MD, PhD, is an Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina, and is on faculty at Duke Regional Hospital and the Duke Clinical Research Institute. He received his medical degree from Duke School of Medicine and completed his residency at Duke Hospital. He then completed his fellowships in gastroenterology and transplant hepatology at Duke School of Medicine. Dr. Julius Wilder obtained the first combination MD/PhD in Medical Sociology in the history of Duke University.

    Dr. Wilder studies how fundamental causes of disease like race, gender, education, and wealth contribute to adverse health outcomes and health disparities. His research has highlighted the need for increased minority participation in clinical trials and documented the safety and efficacy of direct-acting antivirals for treating hepatitis C in African Americans. Dr. Wilder is a principal investigator or co-principal investigator on multiple clinical trials in hepatology and has received research awards for his work on social determinants of disparities in gastroenterology and hepatology, including the 2018 AASLD Foundation Clinical, Translational, and Outcomes Research Award.

    Vinay Sundaram (Moderator)

    Vinay Sundaram, MD, MS is atransplant hepatologist at Cedars-Sinai Medical Center, where he serves asassistant medical director of liver transplantation and director of hepatologyoutcomes research. He has been a member of the AASLD since 2009. He is activelyinvolved with numerous committees including the AASLD membership andmentorship committee, chair of the education subcommittee for the clinicalpractice special interest group.  In addition, he is on themembership and professional standards committee for UNOS. His researchinterests include end-stage liver disease, acute on chronic liver failure andpost-transplant outcomes. He has over 100 published manuscripts and abstractsand is on the editorial board for Hepatology Communications. 

    Raymond Chung (Moderator)

    Raymond Chung, MD, FAASLD is Director of Hepatology and the Liver Center, Vice Chief of Gastroenterology and the Kevin and Polly Maroni Research Scholar atMassachusetts General Hospital. He has been an internationally recognizedresearcher in the areas of HCV virology and pathogenesis. He directs an NIHCooperative Center for Human Immunology centered on HCV, and is co-PI of theHarvard HBV Consortium of the NIH HBV Research Network. He is contact PI of hisDivisional T32 Training Grant, and holds several NIH R01 grants and an NIH K24Mentorship Award.

    He was recently Associate Editorof HEPATOLOGY and has previously served as a Councilor at Large for the AASLD.He has also served as co-Chair of the AASLD/IDSA HCV Guidance panel which ischarged with issuing treatment recommendations for hepatitis C. He has authoredmore than 300 original articles, reviews, and editorials.

  • 2021 Webinar: NASH Congressional Briefing

    Contains 1 Component(s) Recorded On: 09/29/2021

    Webinar hosted by the American Association for the Study of Liver Diseases and Global Liver Institute on Wednesday, September 29.

    The Non-alcoholic steatohepatitis (NASH) Congressional briefing co-led by The American Association for the Study of Liver Diseases (AASLD) and Global Liver Institute (GLI) focused on establishing a national strategy to advance prevention, treatment, and diagnosis of NASH, the most severe form of nonalcoholic fatty liver disease.

  • 2021 Webinar: How Patients Can Get Involved with AASLD The Liver Meeting®

    Contains 2 Component(s) Recorded On: 09/22/2021

    Webinar hosted by the Public Policy Committee on Wednesday, September 22.

    The Liver Meeting®, held by the American Association for the Study of Liver Diseases, brings together attendees from around the world to exchange the latest research, discuss new developments in treatments and network with others in the field. This year's annual meeting will be held November 12 - 15, 2021. It will be a digital only meeting. This scientific meeting has expanded greatly in the past few years to include opportunities for patients and patient advocates to engage in meaningful participation. There are special presentations that summarize key scientific findings released at the meeting and break down how the information can be useful for patients and advocates in their work and lives. There are also many networking opportunities through the annual patient advocates forum and the patient connection and community lounge. This webinar will provide an opportunity for patients and patient advocates to learn more about AASLD, The Liver Meeting®, patient advocate sessions being planned this year, how they can participate in this year's conference and share any feedback.

    Meena B. Bansal

    Meena B. Bansal, MD, FAASLD is currently Professor of Medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai, Deputy Chief Medical Officer for Mount Sinai Health Partners, and Vice President, Population Health for Quality and Efficiency. Dr. Bansal attended Harvard University and then Cornell Medical School. She completed her internship and residency at Cornell Medical School and her Gastroenterology Fellowship at the University of Pennsylvania in 2001.

    Dr. Bansal joined the faculty at Mount Sinai in 2001 and from 2002-2009 she served as Transplant Hepatology Fellowship Director, leading one of the largest transplant hepatology fellowships in the United States. While remaining clinically active, she developed an NIH-funded basic research program focusing on understanding underlying molecular mechanisms of liver fibrosis and stellate cell biology in an effort to develop novel anti-fibrotic therapies. Her current research interests focus on the impact of HIV on hepatic inflammation and fibrosis. She became the Director of Translational Research in the Division of Liver Diseases in 2013 and has been principal investigator for numerous clinical trials ranging from HCV to NASH. In 2013, she became the Medical Director of all Hospital-based Clinics at Mount Sinai. In this latter role she developed an interest in population health and the challenges of the evolving health care landscape. Over the past 5 years, her focus has also been on building a population health infrastructure that will allow a large academic health system to be successful in value-based care.

    Karen Hoyt

    Karen R. Hoyt is a patient advocate at ihelpc.com, Your Best Friend’s Guide to Chronic Liver Disease. She is also a Language Arts teacher who was diagnosed with chronic liver disease, hepatocellular carcinoma, and is a liver transplant recipient. She is the author of The Liver Loving Diet.

    After successful treatment for hepatitis C in 2012, she began a website to encourage and inform patients, which led to other speaking and writing engagements about her experience living with liver disease. When she was diagnosed with hepatocellular carcinoma, she completed her book, The Liver Loving Diet to provide health and nutritional tips for those with CLD. While receiving chemotherapy treatments, she began training for the World Transplant Games. After her life saving liver transplant, she went on to receive the gold medal in cycling in her division in Malaga, Spain.

    Karen serves on the American Association for the Study of Liver Disease (AASLD) COVID-19 task force and other committees as a patient advocate. She is a graduate of and speaker to the Global Liver Institute’s (GLI) Academy. She is the Vice President and Co-Founder of Transplant Recipients International (TRIO) Oklahoma chapter, a member of National Viral Hepatitis Roundtable (NVHR), serves as a committee member for the World Transplant Games Federation (WTGF) and a member of the World Hepatitis Alliance. She has coauthored peer reviewed articles for such journals as HEPATOLOGY and Clinical Liver Disease.

    Ryan Clary (Moderator)

    Ryan Clary is a non-profit executive with over 25 years of experience in HIV, viral hepatitis and health care advocacy. Most recently, he served as the Executive Director of the National Viral Hepatitis Roundtable where he developed and oversaw the organization’s public policy, programmatic, communications and fundraising strategies.

    Since 2018, Ryan has served as a consultant with End the Epidemics: Californians Mobilizing to End HIV, viral hepatitis, STIs and overdose. In that role, Ryan coordinates and provides strategic input to the coalition of over 300 organizations committed to these epidemics. He also consults with the San Diego Hepatitis C Task Force by providing technical assistance to stakeholders developing a strategic plan to eliminate hepatitis C in San Diego and with the California TB Controllers Association to strengthen and grow the Coalition for a TB-free California.

    In April 2021, Ryan was named co-chair of the Los Angeles County Hepatitis C Task Force. In August 2021, he was selected as a member of the Hep B United National Advisory Board.

  • 2021 Webinar: Biliary Atresia: Where We Are and Where Do We Go from Here?

    Contains 2 Component(s) Recorded On: 09/02/2021

    Webinar hosted by the Pediatric Liver Disorders Special Interest Group on September 2, 2021.

    Biliary atresia (BA) is a rapidly progressive inflammatory fibro-obliterative process affecting intra and extra hepatic bile ducts. BA is the most common indication for liver transplantation in children, however the etiopathogenesis is not completely understood. This one hour webinar will summarize genomics in BA, current diagnostic algorithms and novel prognosticators for BA, and long term outcomes of BA. Learners will gain understanding of current practices and future directions in etiopathogenesis and outcomes of BA.

    Kathleen M. Loomes

    Kathleen M. Loomes, MD, FAASLD is a Professor of Pediatrics in the Division of Gastroenterology, Hepatology and Nutrition at The Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine. Dr. Loomes is Director of the Fred and Suzanne Biesecker Pediatric Liver Center at The Children’s Hospital of Philadelphia. She is engaged in clinical and translational research focused on pediatric cholestatic liver diseases, such as biliary atresia, Alagille syndrome and PFIC. 

    Dr. Loomes has served as an editorial board member for HEPATOLOGY and Cellular and Molecular Gastroenterology and Hepatology. In the AASLD, she is a past Chair of the Pediatric Special Interest Group and a current member of the Nominations Committee. Dr. Loomes has also served as a standing member of the Hepatobiliary Pathophysiology Study Section for NIH (2016-20). Dr. Loomes is the Principal Investigator at CHOP for the NIDDK-funded Childhood Liver Disease Research Network and the Pediatric Acute Liver Failure Immune Response Network. Her primary research interests are in the genetic susceptibility to biliary atresia and genetic modifiers of the clinical phenotype in Alagille syndrome. Dr. Loomes is the PI of the Pediatric GI T32 at CHOP and Director of Fellows’ Research for the Division of Gastroenterology, Hepatology and Nutrition. 

    Sanjiv Harpavat

    Sanjiv Harpavat, MD, PhD is an Assistant Professor at Baylor College of Medicine and Texas Children’s Hospital. He is a pediatric gastroenterologist with special interests in neonatal cholestasis, genetic causes of liver disease such as progressive familial intrahepatic cholestasis and Wilson disease, liver transplantation, and non-alcoholic fatty liver disease. His clinical and translational research focuses on the serious liver condition biliary atresia (BA). Dr. Harpavat leads an NIH-funded multi-hospital screening initiative for BA, as well as clinical trials of novel medications to help improve outcomes in BA after the Kasai operation.

    Saul J. Karpen

    Saul J. Karpen, MD, PhD, FAASLD is pediatric hepatologist, Professor of Pediatrics, Raymond F. Schinazi Distinguished Biomedical Chair, Chief of the Division of Pediatric Gastroenterology, Hepatology, and Nutrition at Emory University School Medicine/Children’s Healthcare of Atlanta. The overarching aim of his research is to understand cholestasis, with the goal of discovering and implementing rational molecular targets, focusing upon nuclear receptors and transporters. Recent research along these lines includes discovering genetic contributions to biliary atresia (BA; PKD1L1 and other genes) and use of IBAT inhibitors in global clinical studies of BA and other cholestatic diseases of childhood. On a national and international basis, he is engaged in leadership of the Liver Forum’s Pediatric Cholestatic Disease Working Group and two NIDDK-supported consortia for liver disease: ChiLDReN and NASH CRN.

    Krupa R. Mysore (Moderator)

    Krupa R. Mysore, MD, MS is an Assistant Professor of Pediatrics, Section of Gastroenterology, Hepatology and Nutrition, Texas Children’s Hospital, Baylor College of Medicine. Her clinical and research interests are in pediatric liver diseases such as biliary atresia and liver transplantation. She is a board-certified transplant hepatologist and has a master’s degree in Clinical Investigation. Her laboratory work focuses on basic and translational projects designed to establish how immune dysregulation in chronic liver disease alters hosts susceptibility to infection. She is a recipient of the AASLD 2019 Clinical, Translational and Outcomes Research Award.

    Dr. Mysore is a member of the Pediatric Liver Disorders, Liver Transplantation and Surgery, and Cholestatic and Autoimmune Liver Diseases Special Interest Group. She has served previously on executive committee of American Society of Transplantation and research Subcommittee of The Society for Pediatric Liver Transplant. She serves as site PI of national multicenter pediatric transplant clinical trial. Her recent publications related to my clinical and research interests includes Mysore KR, Shneider BL, Harpavat S. Biliary Atresia as a Disease Starting In Utero: Implications for Treatment, Diagnosis, and Pathogenesis. J Pediatr Gastroenterol Nutr. 2019 Jul 22.doi: 10.1097/MPG.0000000000002450 and Mysore KR, Phan TL, Himes RW, Schady D, Eldin KW, Prusty BK, Munoz FM. Human Herpesvirus 6 Infection in Pediatric Liver Transplantation: Single-Center Study of Incidence, Outcomes, and Management. J Pediatric Infect Dis Soc. 2021 May 28;10(5):599-606. doi: 10.1093/jpids/piaa166. PMID: 33491073; PMCID: PMC8163056.

  • 2021 Webinar: Genetics of NAFLD

    Contains 2 Component(s) Recorded On: 07/27/2021

    Webinar hosted by the Nonalcoholic Fatty Liver Disease Special Interest Group on July 27, 2021.

    In this webinar, you will learn how to describe nonalcoholic fatty liver disease (NAFLD) as it relates to genes in animal and human models, their role, function and related pathways. Also, the focus on NAFLD-related genes in human studies and their relationship to disease severity. Lastly, can you use the genes in a precision medicine approach?

    Silvia Sookoian

    Silvia Sookoian, MD, PhD, FAASLD is head of Clinical and Molecular Hepatology Department, Institute of Medical Research IDIM-National Scientific and Technical Research Council (CONICET), School of Medicine, University of Buenos Aires. She is also the Vice-Chair of Institute of Medical Research, IDIM-CONICET, School of Medicine, University of Buenos Aires. Dr. Sookoian received her medical degree with honors in the University of Buenos Aires, Scholl of Medicine (magna cum laude). She completed her residency in Internal Medicine in Cosme Argerich Hospital Associated to the University of Buenos Aires. Argentina. She received her PhD degree in Molecular Medicine in the University of Buenos Aires. Argentina. She has been in clinical practice since 1987 (Clinical Training Board certificated in Internal Medicine; Fellowship in Hepatology). She received training in Hepatology (Hepatology Centers of Excellence Program Sweden), GI–Liver pathology (Armed Forces Institute of Pathology, Washington DC), and genetics of complex diseases (Cold Spring Harbor Laboratories USA and Wellcome Trust Advanced Courses). She was awarded as Fellow of the American Association for the Study of Liver Diseases (FAASLD), which recognizes superior professional achievement in liver research and practice.

    Dr. Sookoian’s current clinical and translational research is focused on genetic, epigenetic, and molecular mechanisms implicated in non-alcoholic fatty liver disease pathogenesis and disease progression. She is involved in both clinical and basic research. She co-authored 172 peer-reviewed on manuscripts on the field of liver diseases. She was involved in pioneer studies on genetics, epigenetics, and tissue microbiome of NAFLD, and the use of OMICs resources to understand the disease biology.  

    Yaron Rotman

    Yaron Rotman, MD, MSc, FAASLD is a clinical investigator and acting chief of the Liver and Energy Metabolism Section in the Liver Diseases Branch of NIDDK. He received his MD and MSc in Neurophysiology degrees from the Hebrew University Hadassah Medical School in Jerusalem, Israel. He subsequently trained in Internal Medicine and Gastroenterology and Hepatology at the Rabin Medical Center in Petach-Tiqva, Israel, before joining the NIDDK Liver Diseases Branch as a fellow, and subsequently as a principal investigator.

    Dr. Rotman’s research focuses on mechanistic questions in non-alcoholic fatty liver disease (NAFLD), the most common liver disorder in the western world. He is utilizing mechanistic clinical trials, human genetics, animal models and in vitro systems to understand mechanisms of hepatic fat accumulation and associated injury. 

    Luca Valenti

    Luca Vittorio Valenti, MD, PhD is an associate professor of Internal Medicine and physician scientist for the Department of Transfusion Medicine and Hematology at Fondazione IRCCS Ca’ Granda Ospedale Policlinico Milano, Italy. His main research interest is understanding the molecular basis of metabolic liver diseases, in particular FLD, iron overload disorders and liver cancer, and to apply these discoveries to the clinical management of patients, through the identification of novel biomarkers, therapeutic strategies and clinical algorithms, in a personalized medicine approach. In collaboration with his international network, he has recently discovered new genetic determinants of FLD. In the iron field, he contributed to establishing the role of body iron accumulation in the pathogenesis of metabolic and cardiovascular complications of insulin resistance, and the therapeutic utility of iron depletion. He uses a variety of tools ranging from epidemiological studies in large cohort of individuals with liver biopsies to human and molecular genetics to understand how a gene mutation results into a phenotype.

    Prof. Valenti has served as reviewer for several international Journals (>60) including New England Journal of Medicine, The Lancet, Gastroenterology, Gut, Journal of Clinical Investigation, HEPATOLOGY, Journal of Hepatology, Nature Communications, Circulation, Diabetes, Blood, several Scientific Societies (EASL, AISF), European Institutions. Since 2019, he is Honorary Member of Institute of Hepatology at the King’s College of London, the Liver Trust. He is considered an opinion leader in the field of metabolic liver diseases, as testified by invited talks and moderations of scientific sessions in scientific meetings and seminars in Italy, Europe, Asia, and the USA.

    Anna Mae Diehl (Moderator)

    Anna Mae Diehl, MD, FAASLD is currently the Florence McAlister Professor of Medicine at Duke University.  She is a physician scientist and academic hepatologist.  Her lab-based research activities focus on basic mechanisms of liver repair and complement her translational/clinical research programs in alcoholic- and nonalcoholic fatty liver disease.  In the past two years, Dr. Diehl she has co-authored ten peer-reviewed manuscripts on these topics.

    Her basic research program has enjoyed uninterrupted NIH RO1 support since 1990 and she has been the Principal Investigator for the NASH CRN UO1 clinical research program at Duke since its inception over 15 years ago. Dr. Diehl’s research contributions to the fields of regenerative medicine, alcohol-related liver disease and NAFLD have been acknowledged by election for membership in the American Society for Clinical Investigation, Interurban Clinical Club, Association of Academic Professors and Johns Hopkins University Society of Scholars, as well as awards such as an NIH/NIAAA Merit Award, the NIAAA Mendelson Award, the Duke Distinguished Faculty Award, and the AASLD Distinguished Scientific Achievement Award. 

    Dr. Diehl has been an associate editor/editorial board member for major journals such as HEPATOLOGY, Gastroenterology, GUT, The American Journal of Physiology, The Journal of Clinical Investigation, Nature Reviews, and eLife.  In addition, she has served as a standing member of several NIH study sections and scientific advisory councils for NIDDK, NCI, NIAAA, the American Liver Foundation, the Alcoholic Beverage Medical Research Foundation, NIDDK Digestive Disease Centers at Baylor, USC and U Pittsburgh, and NIAAA Alcohol Research Centers at U Louisville and the Cleveland Clinic.  

  • 2021 Webinar: Gaps in Advance Care Planning at Transplant Centers: Call for Action

    Contains 2 Component(s) Recorded On: 07/13/2021

    Webinar hosted by the Public Health/Health Care Delivery on July 13, 2021.

    There is increasing interest to integrate palliative care (PC) within routine practice of decompensated cirrhosis to enhance and inform clinical care. It has shown to improve patient- provider communication, provider awareness of symptoms, tailored symptom management enhance quality of life, ultimately with a better end of life care. There is minimal knowledge on what key elements of PC can inform care, particularly if advance care planning (ACP) has a role to play within Transplant Evaluation. 

    Arpan A. Patel

    Aran A. Patel, MD, PhD is a transplant hepatologist and health services researcher at the David Geffen School of Medicine at UCLA. He is also a staff physician at the West Los Angeles Veterans Affairs Center and core investigator at the VA Center for the Study of Healthcare Innovation, Implementation and Policy (CSHIIP) in Los Angeles. He performed his residency in Internal Medicine at the Hospital of the University of Pennsylvania, followed by fellowship in gastroenterology at UCLA and fellowship in Transplant Hepatology at Mount Sinai. He completed a PhD in Health Policy and Management at the Fielding School of Public Health at UCLA in 2020. 

    Dr. Patel’s career goal is to ensure that patients with advanced liver disease receive high-value care that optimizes their quality of life. His research goal is to understand ways that principles of palliative care can be integrated in management of these patients and their caregivers.

    Manisha Verma (Moderator)

    Manisha Verma, MD, MPH, currently serves as the Director of Research at the Department of Digestive Diseases and Transplantation at Einstein Healthcare Network, Philadelphia, and as the Assistant Professor of Medicine, Research at Sidney Kimmel Medical College. Her program of research focuses on patient centered outcomes research (PCOR) within Hepatology and beyond.  She and her team received a 15 million research award from the Patient Centered Outcomes Research Institute to conduct a multi-site cluster randomized study to compare two models of palliative care delivery for ESLD. She has contributed to advances in knowledge of clinical applications of Health Services Research, specifically in the areas of clinical integration of patient reported outcomes assessments,  integrated care models (palliative care and behavioral health), and population-based health approaches. 

    In her role, she is responsible for promoting and facilitating leading edge research, including collaborative and interdisciplinary research, in areas related to the mission of the Department (to advance patient care, education and new treatments for liver diseases). She serves as the Steering Committee member for the American Association for Study of Liver Diseases (AASLD) Public Health / Healthcare Delivery Group and as the Vice Chair for the Education Subcommittee. Dr. Verma has won both the Albert Einstein Society Innovative Awards and Albert Einstein Society Research Awards as a Principal Investigator since 2015 onwards.  The studies supported from these awards have led to development of a PCOR Pillar within the Department. 

    Brett E. Fortune (Moderator)

    Brett E. Fortune, MD, MSc, is a transplant hepatologist who works at New York Presbyterian/Weill Cornell for the Center for Liver Disease and Transplantation. Dr. Fortune has a clinical focus to provide excellent care for patients with advanced liver disease and those who need or have received liver transplantation.

    Dr. Fortune’s research interests include clinical outcomes related to complications of cirrhosis and portal hypertension as well as quality improvement in the care of patients with cirrhosis or those who have received a liver transplant.

  • Fundamentals of Liver Disease - Cirrhosis 2.0

    Contains 31 Component(s), Includes Credits Recorded On: 07/12/2021

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    DESCRIPTION
    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    KEY TOPIC AREAS
    Does My Patient Have Cirrhosis?
    Natural History of Cirrhosis and General Management of the Compensated Patient
    Varices and Variceal Hemorrhage
    Ascites
    Hyponatremia and Hepatorenal Syndrome
    Hepatic Encephalopathy
    Infections in Cirrhosis
    Pulmonary Complications in the Patient with Cirrhosis
    Does my Patient with Cirrhosis Need to be Referred for Liver Transplant?

    Release date: July 12, 2021
    Expiration date: July 11, 2024
    Time to complete each module: 30 minutes

    CREDITS OFFERED
    Continuing Medical Education (CME): For a maximum of 4.50 AMA PRA Category 1 Credits™  
    Continuing Education (CE): For a maximum of 4.50 Contact Hour 
    You may only earn one Continuing Education Credit type - either CME or CE

    Maintenance of Certification (MOC): For a maximum of 4.50 MOC Points

    COMPONENTS
    Online presentations comprised of:
    -9 online interactive, narrated modules 20 to 25 minutes in length
    -Pre- and post-test questions for each module
    -Evaluation for CME or CE credit offering 

    DIRECTIONS
    Click "Register" to activate the enduring material. Review all section tabs before you begin. Select module of interest. Complete all components to claim either CME or CE. MOC is available for learners who complete and earn CME.

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2021 AASLD. 

    CONTACT INFORMATION 
    For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org 
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    Learning Objectives:
    • Identify patients with liver disease
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for different liver diseases
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Pharmacists
    Physician Assistants
    Transplant Coordinators
    Surgeons
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 4.50 AMA PRA Category 1 Credits™ 
    Maintenance of Certification (MOC): For a maximum of 4.50 MOC Points
    Continuing Education (CE): For a maximum of 4.50 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS  Continuing Medical Education (CME) 
    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  
    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 4.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS 
    Physicians and other health care professionals for a maximum of 4.50 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by July 11, 2024

    CLAIMING CE CREDITS
    Nurses for a maximum of 4.50 contact hours for this enduring continuing education material must be completed by July 11, 2024

    CLAIMING ABIM MOC POINTS  
    Physicians seeking ABIM MOC credit must complete the enduring material by July 11, 2024. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through July 2024 for individuals who successfully complete MOC.

    HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-tests

                 o    Watch video presentations

                 o    Complete the post-tests and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing  score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    Patrick Kamath

    Patrick S. Kamath MBBS, MD, DM is Professor of Medicine and Consultant in Gastroenterology and Hepatology at the Mayo Clinic College of Medicine and Science, Rochester, Minnesota. He graduated in 1976 from St John’s Medical College in Bangalore and subsequently, underwent postgraduate training at the Postgraduate Institute of Medical Education & Research (PGIMER) in Chandigarh, the premier medical post-graduate training Institute in India. He received the Jane and Camillo Patrao Prize in Medicine at St John’s Medical College, and the Kataria Gold Medal (an award for the most outstanding postgraduate student) at the PGIMER.  He completed both his MD in Medicine (1980) and is DM in Gastroenterology (1982) at the PGIMER.  On his return to Bangalore in January 1983 he joined St John’s Medical College, Bangalore University and quickly rose to the position of Associate Professor and then Professor and Chief at the Department of Gastroenterology. At a national and international level, Patrick S. Kamath has been honored with the Distinguished Educator Award of the American Gastroenterology Association in 2015 and the Distinguished Educator/Mentor award of the American Association for the Study of liver Diseases in 2018. He delivered the Eugene Schiff oration at the AASLD annual meeting in 2017. 

    Professor Kamath’s academic research has appeared in top-ranking journals including the New England Journal of Medicine, Nature Genetics, the Lancet, British Medical Journal, Gastroenterology, Hepatology, and the Journal of Hepatology.  He has served as Associate Editor at different times for the foremost journals in the field: Hepatology, Clinical Gastroenterology and Hepatology, and Journal of Hepatology. With more than 500 papers to his name, he has published widely in various fields, but particularly in the study of clinical outcomes related to cirrhosis and portal hypertension, vascular diseases of the liver, and polycystic liver disease.  He has written over 100 chapters in standard texts.  However, he is mostly known for his work in the development of the Model for End-Stage Liver Disease (MELD) score.  

    Guadalupe Garcia-Tsao

    Guadalupe Garcia-Tsao, MD, FAASLD is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.

    Juan G. Abraldes

    Juan G. Abraldes, MD is a Transplant Hepatologist, Professor and Director of the Liver Unit at the University of Alberta, Edmonton, Canada. He gained his MD in 1995 from the University of Santiago de Compostela, Spain, and got his Board Certificate in Gastroenterology and Hepatology at the Liver Unit, Hospital Clinic, University of Barcelona (2000). He did a postdoctoral training at Yale University (2003–2004).

    He has published over 200 manuscripts on the pathophysiology, diagnosis and management of end-stage liver disease. He has co-authored the international Baveno guidelines for the management of portal hypertension in 2005, 2010 and 2015. He is the co-author of the American Association for the Liver Clinical Guidance for the management of varices and variceal bleeding in cirrhosis. He was the chair of the AASLD Portal Hypertension Special Interest Group from 2017-2018.

    Florence Wong

    Florence Wong, MD is a full professor at the University of Toronto and staff Hepatologist at the Toronto General Hospital, Ontario, Canada. She received her medical degree from the University of Melbourne, Australia and completed her postgraduate training in Australia and in Toronto, Canada. Apart from caring for a large population of patients with advanced liver cirrhosis, Dr. Wong has been active in research in the pathogenesis of portal hypertension, ascites formation, liver-kidney interaction, including the development of hepatorenal syndrome, and renal failure in cirrhosis for the past 28 years. She has received research funding from various funding agencies including the Canadian Institutes of Health Research, Canadian Liver Foundation and the National Institutes of Health.

    She has been the Secretary of the International Ascites Club, organizing two international meetings on the complications of ascites, she also held the position as the Chair of the Education Committee of the Canadian Association for the Study of the Liver. Recently, she served as the Chair of the "Acute-on-Chronic Liver Failure Special Interest Group" of the American Association for the Study of the Liver, and organizer of the Single Topic Symposium of Acute-on-Chronic Liver Failure. Currently, she is the Deputy Editor of Liver Transplantation. She is also the recipient of the Gold Medal from the Canadian Liver Foundation and the Canadian Association for the Study of the Liver for her contribution to academia in Hepatology.

    She has published widely on the topics related to ascites, and renal dysfunction in cirrhosis. She has more than 200 peer-reviewed publications as well as contributing regular reviews, book chapters and editorials on similar topics. She is currently on the writing committee to write the guidelines for the management of refractory ascites for the American Association for the Study of the Liver. Most recently, she has been responsible for putting together a landmark international document defining renal failure in cirrhosis.

    Raimund Pichler

    Raimund Pichler, MD is an Associate Professor of Medicine at the University of Washington in Seattle, WA. Dr. Pichler is a board-certified Nephrologist and director of the Kidney-Liver program at the University of Washington. His clinical focus is to improve patient care of patients with renal issues associated with liver disease or liver transplantation. 

    Dr. Pichler has been a Co-Investigator in several hepatology related trials and has been teaching and mentoring Medical Students, Residents and Fellows at the University of Washington for almost two decades. Dr. Pichler has been on the editorial board of several Nephrology journals and has lectured both nationally and internationally.  

    Jasmohan S. Bajaj

    Jasmohan S. Bajaj, MBBS, MD, MS, FACG, AGAF, FRCP, FAASLD is Professor of Medicine, Division of Gastroenterology, Hepatology, and Nutrition at Virginia Commonwealth University and Richmond, VA Medical Center in Richmond, VA. He is a Fellow of the American College of Gastroenterology, American Gastroenterological Association, American Association for the Study of Liver Diseases, was elected to the Fellowship of the Royal College of Physicians in London and to the American Society for Clinical Investigation. Dr. Bajaj earned his MBBS from Delhi University at Maulana Azad Medical College. He completed an internship in internal medicine at Delhi University at Maulana Azad Medical College and internal medicine residency at the State University of New York Health Science Center in Brooklyn. He furthered his medical training with a fellowship in gastroenterology and hepatology at the Medical College of Wisconsin Affiliated Hospitals, then went on to earn an MS in epidemiology at the Medical College of Wisconsin in Milwaukee.

    Active in research, Dr. Bajaj has served as a principal investigator or co-investigator for numerous clinical trials in areas such as hepatic encephalopathy, chronic liver disease and microbiome. Dr. Bajaj’s research has been funded through the NIH, US Veterans Affairs, AHRQ, and American College of Gastroenterology. His work has been published in Nature, New England Journal of Medicine, Gastroenterology, Journal of Hepatology, Hepatology, The American Journal of Gastroenterology, and Liver Transplantation, among others. Dr Bajaj is the upcoming Co-Editor in Chief for the American Journal of Gastroenterology and is currently an associate Editor for the Red Journal and Gut Microbes. He is on the editorial board for Journal of Hepatology, Hepatology, and Liver Transplantation. He was a member of the AASLD/EASL Hepatic Encephalopathy Guidelines Writing Committee, is the Chairperson of the Acute-on-Chronic Liver Failure ACG Clinical Guidelines and a member of the AASLD ICU and ACLF Guidance committee. He is also a member of the AASLD Clinical Research Committee. Dr Bajaj is the Chairperson for the North American Consortium for Study of End-Stage Liver Disease and was the immediate Past President of the International Society for Hepatic Encephalopathy and Nitrogen Metabolism.

    Puneeta Tandon

    Puneeta Tandon, MD, FRCPC is an associate professor of medicine, co-director of the Cirrhosis Care Clinic and transplant hepatologist at the University of Alberta in Edmonton, Alberta, Canada. She completed her internal medicine, hepatology and clinical epidemiology training at the University of Alberta with additional training at Yale University and the Hospital Clinic in Barcelona.

    Dr. Tandon’s clinical practice and research are focused on cirrhosis with research interests including cirrhosis related complications, malnutrition, frailty, exercise therapy, palliative care and integrative health approaches such as meditation and behavior change techniques. It is her career goal to provide wholistic, interdisciplinary, patient-centered care through evidence, education, empowerment, engagement and teamwork.


    Michael B. Fallon

    Michael B. Fallon, MD, FAASLD is Professor and Chair of the Department of Medicine at the University of Arizona College of Medicine – Phoenix (UACOMP). A national expert in transplant hepatology and pulmonary complications of cirrhosis, he is actively involved in translational and multicenter clinical studies of hepatopulmonary syndrome and portopulmonary hypertension. He has over 140 publications with 30 years of academic medicine experience including extensive patient care, education, leadership and clinical investigation in internal medicine. In his role as Chair of the Department of Medicine, Dr. Fallon provides executive leadership to many of the multidisciplinary programs at Banner – University Medical Center Phoenix, ten UACOMP divisions, and more than 160 residents and fellows.

    Dr. Fallon has received numerous awards recognizing his accomplishments in academic medicine including teaching, research and innovation.  Additionally, he has held numerous leadership positions in professional organizations including multiple committees of the American Association for the Study of Liver Disease, member of the American Board of Internal Medicine Transplant Hepatology Test Committee for 9 years and is a past senior associate editor of Clinical Gastroenterology and Hepatology.  He also serves as the lead author for the Diseases of the Liver and Biliary System Chapters for Cecil Essentials of Medicine for the past 15 years.

    Paul Martin

    Paul Martin MD, FAASLD is Professor of Medicine and Chief of the Divisions of Gastroenterology and Hepatology at the University of Miami, USA. He is a native of Dublin, Ireland, where he graduated from medical school at University College, Dublin. He specialized in internal medicine and gastroenterology, training initially in Dublin and subsequently in Canada. He trained in hepatology as a Medical Staff Fellow in the Liver Unit, NIH, Maryland, USA. He is Editor-in Chief of Liver Transplantation and Editor of Handbook of Liver Disease. He was previously a Councilor for AST of the American Society of Transplant. He has had a long standing interest in viral hepatitis and organ transplant. 

    DISCLOSURE OF CONFLICTS OF INTEREST

    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The faculty, organizers and reviewers have reported the following disclosures:

    Patrick Kamath, MD
    Faculty
    Advisory Committees or Review Panels: Sequana

    Guadalupe Garcia-Tsao, MD, FAASLD
    Faculty
    Nothing to disclose

    Juan Abraldes, MD
    Faculty
    Nothing to disclose

    Florence Wong, MD, FRACP, FRCPC
    Faculty
    Consulting: Sequana

    Raimund Pichler, MD
    Faculty
    Nothing to disclose

    Jasmahon Bajaj, MD, MS, FACG, AGAF
    Faculty
    Advisory Committees or Review Panels: ALF, ACG
    Consulting: Salix and Norgine 
    Grant/Research Support: Grifols, Salix

    Puneeta Tandon, MD, FRCPC
    Faculty
    Nothing to disclose

    Michael Fallon, MD
    Faculty
    Grant/Research Support: Gore

    Paul Martin, MD, FAASLD
    Faculty
    Grant/Research Support: AbbVie, Gilead, Thera, Mallinckrodt, Viking, Durect and Enanta

    Amanda J. Chaney, DNP, APRN, FNP-BC
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Royalties: Springer Publishing-Author 

    Rena Fox, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Grant/Research Support: Gilead Sciences

    Sonal Kumar, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead Sciences, Intercept and AbbVie 
    Speaker's Bureau: Gilead Sciences and AbbVie
    Grant/Research Support: Gilead Sciences, AbbVie and Intercept

    Adam Mikolajczyk, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    April G. Morris, FNP
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Speaker's Bureau: Gilead, AbbVie, Intercept Pharmaceuticals
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: AbbVie

    Paul Pockros, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Amol Rangnekar, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Raj Vuppalanchi, MD, FAASLD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Susan Zapatka, DNP 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Dominique Clayton 
    AASLD Staff
    Nothing to disclose

    Melissa Morrison
    AASLD Staff
    Nothing to disclose

    Melanie Stanton, CAE
    AASLD Staff
    Nothing to disclose

    Sheryl Morgan 
    Amedco LLC Staff
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support: No commercial support was received for this enduring material activity.

  • 2021 Webinar: NASH as a Cause of Hepatocellular Carcinoma

    Contains 2 Component(s) Recorded On: 06/16/2021

    Webinar hosted by the Nonalcoholic Fatty Liver Disease Special Interest Group on June 16, 2021.

    Learn about epidemiology of NASH-HCC, differences in NASH-HCC compared to other etiologies and prevention and management of NASH-HCC. Presenters will discuss the rising burden of NASH-HCC such as its contribution to liver transplant, morbidity and mortality and cost. Along with differences in gender, presentation, prognosis and screening data, prevention, treatments such as resection versus liver transplant versus other therapies.

    Zobair M. Younossi

    Zobair M. Younossi, MD, MPH, FAASLD is the President of Inova Medicine, Inova Health System as well as Professor and Chairman of the Department of Medicine at Inova Fairfax Medical Campus in Falls Church, Virginia. He is also Chair of Clinical Research at the same institution. Dr. Younossi earned his medical degree from the University of Rochester School of Medicine and Dentistry in Rochester, NY and completed his residency in internal medicine with a fellowship in gastroenterology and hepatology at Scripps Clinic and Research Foundation in La Jolla, California. He initially served as Staff Hepatologist and Senior Researcher at the Cleveland Clinic Foundation in Cleveland, Ohio before establishing the Center for Liver Diseases at Inova Fairfax Hospital, which is now renowned for research related to outcomes research in liver disease and clinical, health services and translational research in non-alcoholic fatty liver disease (NAFLD). He has served as Vice President of Research for Inova Health System and currently serves as its Chair of Research.

     Over the past three decades, Dr. Younossi has pioneered research in NAFLD and has been a leader in the field of patient-reported outcomes (PROs), economic assessment and other areas of outcomes research in liver disease. He leads a number of international efforts related to NAFLD and PROs in liver disease though global collaborations, including the Chair of Global NASH Council and the Global Liver and NASH Registries. Dr. Younossi has authored over 590 articles, 3 books, 6 journal supplements, over 25 book chapters and over 900 abstracts at the international scientific meetings. 

    Julia J. Wattacheril

    Julia Wattacheril, MD, MPH is an associate professor of medicine and director of the Nonalcoholic Fatty Liver Disease program at Columbia University Irving Medical Center. Her clinical and translational work spans the multidisciplinary care of NAFLD patients at all stages of their disease to the investigation of rare genetic variants influencing the development and progression of NAFLD before and after liver transplantation. She currently leads an interdisciplinary research group using semi-automated techniques to identify at-risk and protected phenotypes within the electronic health record (EHR) for genomic analysis.  Of particular interest for clinical outcomes discovered through EHR phenotyping include rapid progression to advanced liver disease, need for transplantation and hepatocellular carcinoma. 

    Dr. Wattacheril is the lead principal investigator for several clinical trials in and serves as the clinical lead for the liver precision medicine initiative at Columbia. Her early pilot work with proteomics and lipidomics in the development of nonalcoholic steatohepatitis (NASH) led to her current efforts investigating the transcriptomic signatures associated with metabolic reprogramming associated with fibrotic NASH.  She co-led a multicenter consortium investigating the clinical risks associated with the development of hepatocellular carcinoma in patients with all etiologies of chronic liver disease, with a particular local focus on diverse populations.  At Columbia, she works closely with the Institute for Genomic Medicine and Center for Precision Medicine and Genomics to integrate genomics into clinical care. She mentors across disciplines including computational geneticists to masters’ program students in nutrition to undergraduates in psychology. She has a commitment to community education especially in communities of color, including faith-based and non-profit sectors. She has served on the Clinical Research Committee for AASLD and is part of multistakeholder groups such as the NIMBLE Consortium and Liver Forum in addition to other professional society memberships. 

    Samer Gawrieh

    Samer Gawrieh, MD is an associate professor of Clinical Medicine and the director of the Hepatology Research Fellowship Program in the Division of Gastroenterology and Hepatology at Indiana University School of Medicine. His clinical and translational research focuses on different aspects of non-alcoholic and alcoholic fatty liver disease including machine learning-based histological phenotyping, genetic modifiers and diagnostics. He also studies hepatocellular carcinoma (HCC) associated with these diseases with a particular focus on non-cirrhotic HCC.

    Dr. Gawrieh is NIH funded to study NAFLD and NASH in persons living with HIV. He is also the Clinical Director of the Data Coordinating Center for the NIH-sponsored alcoholic hepatitis network, a national network of eight leading academic centers in the US that studies different aspects and therapeutics of alcoholic hepatitis. Dr. Gawrieh is a member of the Editorial Board of Clinical Gastroenterology and Hepatology. 

    Fasiha Kanwal (Moderator)

    Fasiha Kanwal, MD, MSHS, AGAF, FAASLD is a professor of medicine and chief of Gastroenterology and Hepatology at Baylor College of Medicine. She also serves as the editor-in-chief for Clinical Gastroenterology and Hepatology, the American Gastroenterological Association clinical practice journal.  She is a nationally recognized authority in health services research and epidemiology of cirrhosis and hepatocellular cancer (HCC). 

    Dr. Kanwal is currently leading a translational research center for the National Cancer Institute Consortium on Translational Research in Early Detection of Liver Cancer (TLC, U01). She also serves as co-PI for the Texas HCC Consortium (THCCC) and as one of the co-Directors for the Texas Collaborative Center for HCC (TeCH). She is also the Director for NIH T32 funded GI fellowship program at Baylor College of Medicine.